Pure Global
NCT05864456

Prizvalve Pro™ Transcatheter Aortic Valve Replacement Study

Evaluation of the Safety and Efficacy of the Prizvalve Pro™ Transcatheter Aortic Valve System in the Treatment of Patients With Severe Aortic Valve Stenosis Disease at High Surgical Risk
Shanghai NewMed Medical Co., Ltd.·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Aortic Valve Stenosis
Drug/Device/Intervention
Prizvalve Pro™ transcatheter aortic valve system
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Shanghai NewMed Medical Co., Ltd.
Location
Shanghai, China
Timeline & enrollment
Phase
N/A
Start date
Jun 29, 2023
End date
May 01, 2028
Enrollment
73 participants
Primary outcome

Composite endpoint event rate at 30 days

Summary

The purpose of this clinical trial is to evaluate the safety and efficacy of the Prizvalve
 Pro™ transcatheter aortic valve system in the treatment of patients with severe aortic
 stenosis who are at high risk of surgery or who are not suitable for surgery.

ICD-10 classifications
Aortic (valve) stenosisAortic (valve) stenosis with insufficiencyCongenital stenosis of aortic valveStenosis of aortaRheumatic aortic stenosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05864456
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05864456 through Pure Global AI's free database. This phase not specified trial is sponsored by Shanghai NewMed Medical Co., Ltd. and is currently Not yet recruiting. The study focuses on Aortic Valve Stenosis. Target enrollment is 73 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.